Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ferris

Showing results (681-690 of 819) with videos related to

Pageof 82
Sort By:
The Lancet. Oncology|July 11, 2025
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysisAllen S Ho, Shao Hui Huang, Brian O'Sullivan, et al.
Journal for Immunotherapy of Cancer|November 17, 2024
Morphine treatment restricts response to immunotherapy in oral squamous cell carcinomaLisa A McIlvried, Andre A Martel Matos, Mona M Yuan, et al.
Science (New York, N.Y.)|March 12, 2005
Complement factor H polymorphism in age-related macular degenerationRobert J Klein, Caroline Zeiss, Emily Y Chew, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2014
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancerLindsey M Kelly, Guillermo Barila, Pengyuan Liu, et al.
Nature Immunology|July 15, 2020
Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunityChang Liu, Ashwin Somasundaram, Sasikanth Manne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2025
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPatricia McCoon, Ying Wang, Zhongwu Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancerLynn M Knowles, Laura P Stabile, Ann Marie Egloff, et al.
Science Advances|February 11, 2021
LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistanceWeiwei Guo, Yue Wang, Min Yang, et al.
Oral Oncology|September 24, 2017
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi, et al.
Cancer Research|September 15, 2017
PD-1 Status in CD8<sup>+</sup> T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck CancerBenjamin A Kansy, Fernando Concha-Benavente, Raghvendra M Srivastava, et al.
Pageof 82

Showing results (681-690 of 819) with videos related to

Sort By:
Pageof 82
The Lancet. Oncology|July 11, 2025
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysisAllen S Ho, Shao Hui Huang, Brian O'Sullivan, et al.
Journal for Immunotherapy of Cancer|November 17, 2024
Morphine treatment restricts response to immunotherapy in oral squamous cell carcinomaLisa A McIlvried, Andre A Martel Matos, Mona M Yuan, et al.
Science (New York, N.Y.)|March 12, 2005
Complement factor H polymorphism in age-related macular degenerationRobert J Klein, Caroline Zeiss, Emily Y Chew, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2014
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancerLindsey M Kelly, Guillermo Barila, Pengyuan Liu, et al.
Nature Immunology|July 15, 2020
Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunityChang Liu, Ashwin Somasundaram, Sasikanth Manne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2025
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPatricia McCoon, Ying Wang, Zhongwu Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancerLynn M Knowles, Laura P Stabile, Ann Marie Egloff, et al.
Science Advances|February 11, 2021
LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistanceWeiwei Guo, Yue Wang, Min Yang, et al.
Oral Oncology|September 24, 2017
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi, et al.
Cancer Research|September 15, 2017
PD-1 Status in CD8<sup>+</sup> T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck CancerBenjamin A Kansy, Fernando Concha-Benavente, Raghvendra M Srivastava, et al.
Pageof 82